Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma
{{output}}
While CAR T has shown superior efficacy in earlier line of therapy [1, 2] for functionally high-risk multiple myeloma (FHRMM), outcomes with its use in later lines (3+) for FHR disease remain unknown. We describe a single-center experience of FHRMM patients (p... ...
